Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Viridian Therapeutics, Inc. (VRDN) had Return on Equity of -22.54% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$0.28M |
|
$-127.12M |
|
-- |
|
$0.28M |
|
$126.55M |
|
$-126.27M |
|
$-0.85M |
|
$-127.12M |
|
$-127.12M |
|
$-127.12M |
|
$-127.12M |
|
$-127.12M |
|
$-127.12M |
|
$-126.27M |
|
$-127.60M |
|
107.88M |
|
107.88M |
|
$-1.05 |
|
$-1.05 |
|
| Balance Sheet Financials | |
$1.08B |
|
$2.77M |
|
$15.96M |
|
$1.10B |
|
$63.79M |
|
$242.16M |
|
$371.34M |
|
$435.14M |
|
$564.07M |
|
$652.10M |
|
$662.10M |
|
113.24M |
|
| Cash Flow Statement Financials | |
$-224.98M |
|
$-153.90M |
|
$331.48M |
|
$212.38M |
|
$164.99M |
|
$-47.40M |
|
$30.37M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.95 |
|
-- |
|
-- |
|
0.27 |
|
0.37 |
|
100.00% |
|
-44460.57% |
|
-44460.57% |
|
-- |
|
-44760.21% |
|
-44760.21% |
|
$-226.31M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.00 |
|
0.02M |
|
|
Return on Equity |
-22.54% |
-19.49% |
|
-11.59% |
|
-14.06% |
|
$5.85 |
|
$-2.10 |
|
$-2.09 |
|